Scholarlink

Purpose of Review <p>to describe and compare the efficacy and safety of the main PTH treatments, namely PTH(1–84) and palopegteriparatide, for the management of hypoparathyroidism.</p> Recent Findings <p>neither PTH (1–84) nor PTH(1–34) have been shown a clear and consistent favorable impact on the 24&#xa0;h urinary calcium excretion normalization, while the positive effect on quality of life is still debated. Recently, the Food &amp; Drug Administration and the European Medicines Agency approved palopegteriparatide as the first true replacement therapy for hypoPT management. Palopegteriparatide is a prodrug of PTH(1–34), administered once daily, and designed to provide continuous exposure to released PTH over a 24-h dosing period. According to phase II and phase III studies, palopegteriparatide seems to fill the gaps identified in existing therapies for hypoPT.</p> Summary <p>Palopegteriparatide is the first real replacement therapy for the management of hypoparathyroidism and seems to fill the gaps identified in existing therapies for hypoPT.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

PTH Substitution Therapy for Chronic Hypoparathyroidism: PTH 1–84 and Palopegteriparatide

  • 期刊论文

  • 发表日期：

    2025年2月22日

查看全文
  • Andrea Palermo,
  • Anda Mihaela Naciu,
  • Yu Kwang Tay Donovan,
  • Gaia Tabacco,
  • Guido Zavatta

摘要

Purpose of Review

to describe and compare the efficacy and safety of the main PTH treatments, namely PTH(1–84) and palopegteriparatide, for the management of hypoparathyroidism.

Recent Findings

neither PTH (1–84) nor PTH(1–34) have been shown a clear and consistent favorable impact on the 24 h urinary calcium excretion normalization, while the positive effect on quality of life is still debated. Recently, the Food & Drug Administration and the European Medicines Agency approved palopegteriparatide as the first true replacement therapy for hypoPT management. Palopegteriparatide is a prodrug of PTH(1–34), administered once daily, and designed to provide continuous exposure to released PTH over a 24-h dosing period. According to phase II and phase III studies, palopegteriparatide seems to fill the gaps identified in existing therapies for hypoPT.

Summary

Palopegteriparatide is the first real replacement therapy for the management of hypoparathyroidism and seems to fill the gaps identified in existing therapies for hypoPT.